Allogene Therapeutics, Inc.
ALLO
$1.44
-$0.09-5.59%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -22.39% | -20.01% | |||
| Gross Profit | 22.39% | 20.01% | |||
| SG&A Expenses | -3.81% | -4.74% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -17.52% | -16.50% | |||
| Operating Income | 17.52% | 16.50% | |||
| Income Before Tax | 18.73% | 14.72% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 18.73% | 14.72% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 18.73% | 14.72% | |||
| EBIT | 17.52% | 16.50% | |||
| EBITDA | 18.56% | 17.33% | |||
| EPS Basic | 19.85% | 16.11% | |||
| Normalized Basic EPS | 15.95% | 20.07% | |||
| EPS Diluted | 19.85% | 16.11% | |||
| Normalized Diluted EPS | 15.95% | 20.07% | |||
| Average Basic Shares Outstanding | 1.42% | 1.66% | |||
| Average Diluted Shares Outstanding | 1.42% | 1.66% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||